RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Corcept Therapeutics Stock

Corcept Therapeutics Equity 2024

Corcept Therapeutics Equity

506.7 M USD

Ticker

CORT

ISIN

US2183521028

WKN

529882

In 2024, Corcept Therapeutics's equity was 506.7 M USD, a 0.98% increase from the 501.8 M USD equity in the previous year.

Corcept Therapeutics Aktienanalyse

What does Corcept Therapeutics do?

Corcept Therapeutics Inc is a biopharmaceutical company specializing in the development of drugs for the treatment of metabolic, hormonal, and cancer-related diseases. The company was founded in 1998 by Dr. Joseph Belanoff, who still serves as the Chief Executive Officer. The history of Corcept Therapeutics is closely linked to the discovery of mifepristone, a drug that acts as an antagonist to cortisol receptors. In 2002, the company acquired the rights to mifepristone from Roussel Uclaf, a subsidiary of Hoechst AG, and developed it into the drug Korlym (mifepristone). Korlym was approved by the U.S. Food and Drug Administration (FDA) in 2012 for the treatment of patients with endogenous Cushing's syndrome, a severe hormone disorder. The core business of Corcept Therapeutics is the research and development of drugs that affect the body's hormonal balance. In addition to Korlym, the company has also brought other innovative drugs to the market aimed at alleviating or even curing the symptoms of hormonal disorders. These drugs include relacorilant, which is currently undergoing Phase III studies for the treatment of patients with Cushing's syndrome. Another division of Corcept Therapeutics is the development of drugs for the treatment of cancer. The company has conducted several clinical trials to test the efficacy of its drug Korlym in treating certain types of cancer, including breast cancer, lung cancer, and prostate cancer. More recently, Corcept Therapeutics has also developed a new drug called Exicure, which focuses on the treatment of liver cancer. Overall, Corcept Therapeutics has built a wide portfolio of products and services targeting patients with different medical needs. The company has also formed partnerships with other companies and research institutes to support its research and development efforts and improve access to its products. The business model of Corcept Therapeutics is based on partnerships with physicians, hospitals, and clinics that utilize its products and services to help patients with metabolic, hormonal, and cancer-related diseases. The company also relies on close collaboration with the FDA and other regulatory agencies to ensure that its drugs meet the highest standards of safety and efficacy. Corcept Therapeutics is headquartered in Menlo Park, California, USA, and currently employs around 250 people. The company has experienced strong growth in recent years, both through the development of new products and the expansion of its business into global markets. In summary, Corcept Therapeutics Inc is a leading biopharmaceutical company specializing in the development of drugs for the treatment of hormone, metabolic, and cancer-related diseases. With its broad portfolio of innovative products and services, the company has made a significant contribution to improving the health and well-being of millions of people worldwide. Corcept Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Corcept Therapeutics's Equity

Corcept Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Corcept Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Corcept Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Corcept Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Corcept Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Corcept Therapeutics stock

What is the equity of Corcept Therapeutics this year?

Corcept Therapeutics has equity of 506.7 M USD this year.

What was the equity of Corcept Therapeutics compared to the previous year?

The equity of Corcept Therapeutics has increased/decreased by 0.98% increased compared to the previous year.

What impact does a high equity have on investors of Corcept Therapeutics?

A high equity is advantageous for investors of Corcept Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Corcept Therapeutics?

A low equity can be a risk for investors of Corcept Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Corcept Therapeutics affect the company?

An increase in equity of Corcept Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Corcept Therapeutics affect the company?

A reduction in equity of Corcept Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Corcept Therapeutics?

Some factors that can affect the equity of Corcept Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Corcept Therapeutics so important for investors?

The equity of Corcept Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Corcept Therapeutics take to change the equity?

To change equity, Corcept Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Corcept Therapeutics pay?

Over the past 12 months, Corcept Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Corcept Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Corcept Therapeutics?

The current dividend yield of Corcept Therapeutics is .

When does Corcept Therapeutics pay dividends?

Corcept Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Corcept Therapeutics?

Corcept Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Corcept Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Corcept Therapeutics located?

Corcept Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Corcept Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Corcept Therapeutics from 11/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/18/2024.

When did Corcept Therapeutics pay the last dividend?

The last dividend was paid out on 11/18/2024.

What was the dividend of Corcept Therapeutics in the year 2023?

In the year 2023, Corcept Therapeutics distributed 0 USD as dividends.

In which currency does Corcept Therapeutics pay out the dividend?

The dividends of Corcept Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Corcept Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Corcept Therapeutics

Our stock analysis for Corcept Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Corcept Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.